Eric A. Adams

InMed Pharmaceuticals is making strides in Alzheimer’s research with its development of a cannabinoid-based compound that aims to protect and rejuvenate brain neurons. During Benzinga’s virtual event on Thursday, InMed president and CEO Eric A. Adams shared detailed insights into the...

On Thursday at 11 a.m. EST, Benzinga will host a Healthcare & Biotech Breakthroughs virtual conference. This online event will bring together industry leaders to discuss recent advancements in healthcare and biotechnology that are transforming patient care and creating new investment avenues....

InMed Pharmaceuticals Inc. (NASDAQ: INM) released its financial results for the third quarter of the fiscal year 2023 which ended March 31, 2023, revealing sales of $1 million, an increase of 234% compared to $309,585 in Q3 2022. Q3 FY 2023 Financial Highlights Gross profit was $192,511 compared...

InMed Pharmaceuticals Inc. (NASDAQ:INM) released financial results for the second quarter of fiscal year 2023 which ended December 31, 2022, revealing revenue of $469,783, a 77% increase compared to $265,092 in Q2 FY 2022. Q2 FY 2023 Financial Highlights Gross profit was $131,163, compared to $...

InMed Pharmaceuticals Inc. (NASDAQ:INM), a leader in research, development, manufacturing and commercialization of rare cannabinoids, released unaudited financial results for the third quarter of the fiscal year 2022 which ended March 31, 2022. Financial and Operational Highlights: For the 9...